The Influence of Aging on the Early Detection, Diagnosis, and Treatment of Breast Cancer

Fletcher Allen Health Care, University Health Center, University of Vermont, 1 South Prospect Street, Third floor, Burlington, VT 05401, USA.
Current Oncology Reports (Impact Factor: 2.89). 02/2005; 7(1):23-30. DOI: 10.1007/s11912-005-0022-0
Source: PubMed


Patterns of care for women with breast cancer vary substantially with patient age. Older patients with breast cancer frequently receive less than standard management, resulting in poorer outcome. At diagnosis, the health status of older women with breast cancer affects survival and treatment decisions. Age-related comorbidity may limit diagnostic tests, narrow treatment options, and significantly increase mortality not related to breast cancer. Yet, for healthy older women with early-stage breast cancer, stage-adjusted survival is similar to that of younger women. Calendar age is not sufficient to encompass the heterogeneity in health status of the elderly. Instead, management of older women with breast cancer should be based on anticipated survival, functional status, and the goals of the patient for treatment. In this review, we evaluate pertinent data and provide guidance for the management of older women with breast cancer.

3 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Quality of life (QoL) in cancer survivors is an important area of research. While data are available about QoL and breast cancer, there is a paucity of research regarding older breast cancer survivors. The purpose of this research was to examine QoL in older women with early stage breast cancer, within the first year of post-treatment survivorship. The specific aims of this study were to: 1) Describe the changes in overall QoL and the four QoL domains of Physical, Psychological, Social, and Spiritual well-being; 2) Examine the effects of a psychoeducational support intervention on QoL outcomes in older women; and 3) Describe nurses' perceptions of their interactions with older breast cancer survivors. A descriptive, longitudinal design was used to answer the research questions. Data for this study were drawn from the Breast Cancer Education Intervention (BCEI), a longitudinal psychoeducational support intervention for women with early stage breast cancer. Fifty women from the BCEI who were 65 years of age and older were included in this sample, of whom 24 were assigned to the Experimental (EX) Group and 26 were assigned to the Wait Control (WC) Group. Data were collected at three time points: baseline, three months, and six months after study entry. Measurement tools included the BCEI Demographics Form, the Quality of Life-Breast Cancer Survey (QoL-BC), and field notes of the BCEI Research Nurses. The QoL-BC survey is a 50-item scale that measures QoL in women with breast cancer. Descriptive statistics, Generalized Estimating Equation (GEE) methods and t-tests were used to answer research questions #1 and #2. Content analysis was used to answer research question #3. Subjects reported good overall QoL at baseline, but QoL declined over six months. Physical and Psychological well-being declined from baseline to six months later. Social well-being initially improved from baseline to three months but declined at six months. Spiritual well-being initially declined at three months and improved at six months. There was insufficient power to detect a difference in the effects of the BCEI Intervention between the two groups. However, the decline in overall QoL was less in the EX Group. Field notes focusing on nurses' perception of their interactions with older women revealed four themes. These themes include: continuing breast-related health, personal health issues, family health issues, and potential stressors. Results from this study suggest that: 1) changes in overall QoL and within the four QoL domains occur over time; 2) decline in overall QoL was lessened by the BCEI Intervention; and 3) concerns after treatment are both breast cancer and non-breast cancer related. Study findings can direct future research in the following areas: 1) identification of specific concerns within each QoL domain that could lead to an increase or decrease in well-being in older breast cancer survivors; 2) interventions tailored to the needs of older breast cancer survivors to maintain, improve, or lessen decline in QoL after treatment; and 3) reconceptualizing QoL in older breast cancer survivors to include non-cancer related factors.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Attrition in follow up is a key limitation of longitudinal studies, especially in cancer patients in developing countries. We did a retrospective analysis of possible factors that resulted in attrition of patients with breast cancer during follow up. This study is a comparison between patients who came for a follow up regularly to our clinic with those who did not but could be contacted on phone or by post. A computerized grouped database was constructed with the following parameters: age, religious community, other co-morbid conditions if present, distance from place of residence to our city, residence in city/ village, initial stage of the disease, type of treatment and disease relapse or death. Using binary logistic regression, disease relapse was found to be the most important cause of non-compliance. The odds ratio for irregularity or loss to follow up of patients with disease relapse was 2.53 (95% CI: 1.17-5.46; p = 0.02) for patients who were alive with disease relapse and 6.1 8 (95% CI: 3.47-11.02; p < 0.001) for patients who had died due to the disease compared with those who were alive and free of disease. The age and place of residence in a village were other significant factors. The odds of attrition due to age were 1.03 (95% CI: 1.01-1.05; p = 0.04) for each year of increase in age and that of residence in a village was 1.85 (95% CI: 1.02-3.36; p = 0.04). Age, disease relapse and residing in a village are important causes of attrition during follow up of patients with breast cancer in India.
    The National medical journal of India 09/2007; 20(5):230-3. · 0.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Optical molecular imaging is a fast-developing field that holds great promise in cancer diagnosis. Over the past two decades, optical imaging has been actively investigated by researchers in both academic and industrial environments. Compared with other imaging modalities like MRI, CT, and ultrasound (US), optical imaging has many advantages. Technological improvements over the past few years have brought improved tissue penetration, sensitivity, and specificity of imaging cancer by optical methods. Novel devices like diffusion optical tomography (DOT) and the miniature endoscope have either been tested in clinical trials or approved by FDA for clinical use. Many of these new technologies can be integrated into or combined with MRI, CT, or US, providing a multimodality approach to further improve the accuracy of cancer diagnosis. Fast computational methods and ever-growing powerful computers make real-time optical imaging possible, bringing us closer to the possibility of on-site diagnosis. Here we review two different optical imaging methods, namely diffusion optical tomography and microendoscopy. DOT uses near-infrared light to noninvasively measure the hemoglobin concentration and resolve spectroscopic information about the tissue, whereas a tumor may manifest itself as a heterogeneous region due to the increased blood flow to the tumor. Like MRI, CT, and US, DOT sensors interrogate the tissue from the outside. Contrast agents like indocyanine green (ICG) may be used to label the suspected tumor for enhanced DOT results. The microendoscope, however, measures fluorescence signal from inside of the body, typically a cavity like the pulmonary pathway or gastrointestinal tract. The small size of the microendoscope (a few millimeters) allows it to be inserted into small pulmonary branches inaccessible to a conventional endoscope. In addition, microendoscopy offers image resolution approximating that of the microscope, making “in-situ” optical biopsy a possibility.
    Current Medical Imaging Reviews 04/2008; 4(2):125-133. DOI:10.2174/157340508784356815 · 0.73 Impact Factor
Show more